For the first time, the FDA completed a generative AI-assisted scientific review pilot, cutting review tasks from days to ...

The Phase III DESTINY-Breast11 trial showed Enhertu followed by THP significantly improved pathologic complete response (pCR) ...

The phase II ROME trial demonstrated that personalized therapy guided by combined tissue and liquid biopsies significantly ...

The first AI-powered companion diagnostic for non-small cell lung cancer has received FDA Breakthrough Device Designation.

Researchers from Karolinska Institutet developed a non-invasive urine test for early prostate cancer detection, utilizing AI, ...

Merck has launched construction of a $1 billion biologics facility in Wilmington, set to become the U.S. production hub for ...

Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical ...

Microbiotica’s MB097, an oral microbiome-based therapy, shows promise in boosting immunotherapy response in melanoma patients ...

The US FDA has cleared the investigational new drug (IND) application to begin clinical trials for BFB-101, a novel gene ...

In the Phase 3 KEYNOTE-689 trial, pembrolizumab (Keytruda) combined with standard care significantly improved event-free survival (EFS) in patients with resectable, locally advanced head and neck ...